SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — May 23, 2012

Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: May 23, 2012 · CIK: 0001213037 · Accession: 0001104659-12-039426

AI Filing Summary & Sentiment

File numbers found in text: 333-180810

Date
May 22, 2012
Author
Not clearly detected
Form
CORRESP
Company
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)

Letter

Re:

AEGIS CAPITAL CORP. 810 7TH Avenue New York, New York 10019

May 22, 2012

VIA EDGAR AND TELECOPY

Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Trovagene, Inc. (the “Company”)

File No. 333-180810

Registration Statement on Form S-1

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we, as representatives of the several underwriters, hereby request acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m., Washington D.C. time, on May 24, 2012, or as soon thereafter as practicable.

The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

(i)

Date of preliminary prospectus: May 8, 2012, as amended on May 18, 2012 and May 22, 2012

(ii)

Dates of distribution: May 8, 2012 — May 24, 2012

(iii)

Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 4

(iv)

Number of prospectuses so distributed: 600

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

Very truly yours,
AEGIS CAPITAL CORP.

Show Raw Text
CORRESP
1
filename1.htm

AEGIS CAPITAL CORP.
 810 7TH Avenue
 New York, New York 10019

May 22, 2012

VIA EDGAR AND TELECOPY

Securities and Exchange Commission
 100 F Street, N.E.
 Washington, D.C. 20549

Re:

Trovagene, Inc.   (the “Company”)

File   No. 333-180810

Registration   Statement on Form S-1

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we, as representatives of the several underwriters, hereby request acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m., Washington D.C. time, on May 24, 2012, or as soon thereafter as practicable.

The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

(i)

Date   of preliminary prospectus: May 8, 2012, as amended on May 18, 2012   and May 22, 2012

(ii)

Dates   of distribution: May 8, 2012 — May 24, 2012

(iii)

Number   of prospective underwriters and dealers to whom the preliminary prospectus   was furnished: 4

(iv)

Number   of prospectuses so distributed: 600

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

Very   truly yours,

AEGIS   CAPITAL CORP.

By:

/s/   Kevin C. McKenna

Name:   Kevin C. McKenna

Title:   Chief Compliance Officer